Cerity Partners’s Ocular Therapeutix OCUL Stock Holding History

Cerity Partners’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-25,406	Closed	-$308K	–	3358
2025 Q4	$308K	Buy	+25,406	New	+$309K	﹤0.01%	2395

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Cerity Partners's OCUL Position: Q1 2026 in Review

Cerity Partners sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 25,406 shares — an estimated $308K sold.

Cerity Partners first reported a position in OCUL in Q4 2025 and held it in 1 quarter. The position peaked at $308K in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Cerity Partners reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
Cerity Partners sold 25,406 Ocular Therapeutix shares in Q1 2026, an estimated $308K.
Cerity Partners first reported a position in Ocular Therapeutix in Q4 2025 and held it in 1 quarter.
Cerity Partners's Ocular Therapeutix position peaked at $308K in Q4 2025.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.